Low “quotient” Lp(a) Concentration Mediates Autoimmune Activation and Independently Predicts Cardiometabolic Risk

Abstract

Objective: We determined whether U-shaped relationships exist between serum lipoprotein[Lp](a) and cardiometabolic risk.

Methods: In population-based nondiabetic and diabetic middle-aged adults (n=1 428 and 241, respectively) who had been genotyped for the LPA rs10455872 A>G polymorphism, we adjusted the Lp(a) concentration for the effects of genotype and other covariates. Via sex-specific equations we estimated expected Lp(a) concentration in each participant, and the quotient between observed to expected Lp(a) values was determined. Lp(a) and Lp(a) quotient tertiles served to identify non-linear associations with outcomes.

Results: Incident 81 cases of diabetes and 128 of coronary heart disease (CHD) developed at 5.1 years’ follow-up. Lp(a) concentration was linearly associated with the LPA genotype, gender, total cholesterol, (inversely) fasting insulin, which together with age formed the variables to derive the equations. In logistic regression for incident diabetes, the low Lp(a) quotient tertile was a predictor (RR 1.95 [95%CI 1.10; 3.47]) alike the low Lp(a) tertile, additively to major confounders. Cox regression models comprising sex, age, LPA genotype, smoking status, systolic pressure and serum HDL-cholesterol disclosed that, compared with the mid-tertile, both low (HR 1.77) and high Lp(a) quotient tertiles significantly predicted incident CHD, especially in women.

Conclusion: Elevated cardiometabolic risk is conferred by apparently reduced circulating Lp(a) assays supporting the notion that “low” serum Lp(a), mediating autoimmune activation, is a major determinant of cardiometabolic risk.

Key words

autoimmune activation - coronary heart disease - diabetes, type-2 - impaired fasting glucose - lipoprotein(a)

• References

• 1 Marcovina SM, Koschinsky ML, Albers JJ et al. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003; 49: 1785-1796
• 2 Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423
• 3 Nordestgaard BG, Chapman MJ, Ray K et al. European Atherosclerosis Society Consensus Panel . European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
• 4 Erqou S, Thompson A, Di Angelantonio E et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 2160-2167
• 5 Holmer SR, Hengstenberg C, Kraft HG et al. Associations of the polymorphisms of apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003; 107: 696-701
• 6 Clarke R, Peden JF, Hopewell JC et al. PROCARDIS Consortium . Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 381: 2518-2528
• 7 Lanktree MB, Anand SS, Yusuf S et al. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circulation Cardiov Genet 2010; 3: 39-46
• 8 Luke MM, Kane JP, Liu DM et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2030-2036
• 9 Trégouët DA, König IR, Erdmann J et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 283-285
• 10 Koch W, Mueller JC, Schrempf M et al. Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene. Ann Human Genet 2013; 77: 47-55
• 11 Qi Q, Workalemahu T, Zhang C et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012; 33: 325-334
• 12 Mora S, Kamstrup PR, Rifai N et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 1252-1260
• 13 Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014; 20: 575-584
• 14 Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18: 1335-1341
• 15 Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10
• 16 Onat A, Hergenç G, Ozhan H et al. Lipoprotein(a) is associated with coronary heart disease in women independent of metabolic syndrome. Coron Artery Dis 2008; 19: 125-131
• 17 Kutyavin IV, Afonina IA, Mills A et al. 3’-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000; 28: 655-661
• 18 De Kok JB, Wiegerinck ETG, Giesendorf BAJ et al. Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum Mutat 2002; 19: 554-559
• 19 Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: 3160-3167
• 20 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 21 Rose G, Blackburn H, Gillum RF et al. Cardiovascular Survey Methods. 2nd Ed. Geneva, Switzerland: WHO; 1982: 124-127
• 22 Ronald J, Rajagopalan R, Cerrato F et al. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke 2011; 42: 2-9
• 23 Almdal T, Scharling H, Jensen JS et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-1426
• 24 Hiraga T, Kobayashi T, Okubo M et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241-244
• 25 Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: a marker of atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000; 102: 179-184
• 26 Arsenault BJ, Lemieux I, Després JP et al. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. CMAJ 2010; 182: 1427-1432
• 27 Onat A, Can G, Örnek E et al. Abdominal obesity with hypertriglyceridemia, lipoprotein(a) and apolipoprotein A-I, determine marked cardiometabolic risk. Eur J Clin Invest 2013; 43: 1129-1139
• 28 Onat A, Can G, Ademoğlu E et al. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013; 61: 27-33
• 29 Onat A, Yüksel H, Can G et al. Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand J Clin Lab Invest 2013; 73: 569-575
• 30 Aggarwal V, Schneider ALC, Selvin E. Low hemoglobin A1c in nondiabetic adults. An elevated risk state? Diabetes Care 2012; 35: 2055-2060